- Ex-Hong Kong leader jailed in fall from 'such a height' February 22, 2017
- AP, HHMI collaborate on expanded science, health coverage February 15, 2017
- Gilead challenges GSK with strong HIV drug data February 14, 2017
- Bolivia reports first yellow fever case in a decade February 10, 2017
- Lundbeck gives up on Alzheimer’s drug, rival to Axovant pill February 8, 2017
- Ibuprofen Lysine Injection, 20 mg /2 mL (10 mg/mL) by Exela Pharma Sciences: Recall – Particulate Matter February 9, 2017
- Well Balance Xanthium & Siler Combo (Bi Yan Pian) Dietary Supplement by Kingsway Trading Inc.: Recall – Product Contains Banned Ephedra Alkaloids February 9, 2017
- FDA Approves Emflaza (deflazacort) to treat Duchenne Muscular Dystrophy February 9, 2017
- Too few U.S. teens getting flu and cancer vaccines February 7, 2017
- Tech giants fight Trump travel ban February 6, 2017
Depakote is a Delayed Release Sodium tablet available in 125 mg, 250 mg (Divalproex sodium equivalent) and 500 mg (Valproic acid equivalent) tablets. The Divalproex sodium is formed by neutralizing (partially) Valproic acid that comes in form of Valproate Semi-sodium (a white powder) with 0.5 equivalent of sodium hydroxide. It also comprises certain inactive ingredients, which are: Cellulosic polymers, Diacetylated monoglycerides, Povidone, pre-gelatinized starch, silica gel, talc, titanium dioxide; vanillin FD&C Blue No. 1 and FD&C Red No. 40 (125 mg tablets); FD&C Yellow No. 6 and iron oxide (250 mg tablets); D&C Red No. 30, FD&C Blue No. 2 and iron oxide (500 mg tablets).
Information you should know
Depakote acts by inhibitory action potentiation of the gamma-amino butyric acid and requires monthly assessments of liver function. The assessments should start before the medication begins and must go through the entire tenure of medication. Blood and urine test are also a must prior to the onset of the therapy. Depakote is not for patients with manic episodes and/or bipolar disorder symptoms. The medicine may induce hypersensitivity related to the active and inactive ingredients; active liver diseases; severe hepatic dysfunction including hereditary and/or chronic ones) and Porphyria (a genetic abnormality of metabolism causing abdominal pains and mental confusion). Diabetics may receive false positive signs in urine tests due to the presence of semi-sodium in the medicine.
Medical supervision is advised for Depakote users with renal insufficiency; with Systemic Lupus Erythematous and with Pregnancy.Depakote is Divalproex sodium formed by neutralizing partially Valproic acid in form of Valproate Semi-sodium (a white powder) with 0.5 equivalent of sodium hydroxide. It also comprises certain inactive ingredients, which are: Cellulosic polymers, Diacetylated monoglycerides, Povidone, pre-gelatinized starch, silica gel, talc, titanium dioxide; vanillin FD&C Blue No. 1 and FD&C Red No. 40 (125 mg tablets); FD&C Yellow No. 6 and iron oxide (250 mg tablets); D&C Red No. 30, FD&C Blue No. 2 and iron oxide (500 mg
Directions for taking Depakote
Depakote is meant to be administered orally and it is not to be chewed. It is meant to be swallowed with plain water. The dosage is set as per age and body weight of the patient. To start off, 750mg (3 X 250mg. Or 2 X 375 mg.) is recommended on a daily basis, which is then increased rapidly to achieve the ideal dose that meets the therapeutic need. The medicine is not recommended for anyone below 18; with
immune disorders; epilepsy and women undergoing lactation.